Logo
Logo

About Bempedoic Acid API

Product
  • Therapeutic CategoryCardiovascular

  • CAS Number

    738606-46-7

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    Brazil DMF

Mechanism of Action

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.

Indication

NEXLETOL is an adenosine triphosphate-citrate lyase (ACL) inhibitor indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Related APIs

Amlodipine Besylate

Cardiovascular

arrow

Apixaban

Cardiovascular

arrow

Bempedoic Acid

Cardiovascular

arrow

Clopidogrel Bisulfate (Form 1)

Cardiovascular

arrow

Clopidogrel Bisulfate (Form 2)

Cardiovascular

arrow

Dabigatran Etexilate Mesylate

Cardiovascular

arrow

Doxazosin Mesylate

Cardiovascular

arrow

Ezetimibe

Cardiovascular

arrow

Fondaparinux Sodium

Cardiovascular

arrow

Lacidipine

Cardiovascular

arrow

Losartan Potassium

Cardiovascular

arrow

Mavacamten

Cardiovascular

arrow

Metoprolol Succinate

Cardiovascular

arrow

Ramipril

Cardiovascular

arrow

Rivaroxaban

Cardiovascular

arrow

Tafamidis Free Acid

Cardiovascular

arrow

Tafamidis Meglumine

Cardiovascular

arrow

Ticagrelor

Cardiovascular

arrow

Treprostinil

Cardiovascular

arrow

Treprostinil Olamine

Cardiovascular

arrow

Valsartan

Cardiovascular

arrow

Atorvastatin Calcium (Amorphous And Form P)

Cardiovascular

arrow

Sacubitril-Valsartan

Cardiovascular

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Description not provided

FAQs

What is the safety guide for Bempedoic Acid API ?
    • 180 mg tablet of bempedoic acid
    • Fixed-dose combination of 180 mg bempedoic acid and 10 mg ezetimibe.
What is Bempedoic Acid API used to treat?
  • It is used to reduce LDL cholesterol levels in statin-refractory patients

What drug class is Bempedoic Acid API?
  • First-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor

What are offerings of Dr. Reddy's for Bempedoic Acid API?
  • We offer anhydrous non-solvated crystalline form

What is the process available for ordering Bempedoic Acid API ?

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.